Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

被引:177
作者
Gould, TD [1 ]
Quiroz, JA [1 ]
Singh, J [1 ]
Zarate, CA [1 ]
Manji, HK [1 ]
机构
[1] NIMH, Mol Pathophysiol Lab, NIH, Bethesda, MD 20892 USA
关键词
depression; mania; pharmacology; manic-depressive illness; neurotrophic factors; valproic acid; PAP phosphatase; pramipexole; zinc;
D O I
10.1038/sj.mp.4001518
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bipolar disorder afflicts approximately 1 - 3% of both men and women, and is coincident with major economic, societal, medical, and interpersonal consequences. Current mediations used for its treatment are associated with variable rates of efficacy and often intolerable side effects. While preclinical and clinical knowledge in the neurosciences has expanded at a tremendous rate, recent years have seen no major breakthroughs in the development of novel types of treatment for bipolar disorder. We review here approaches to develop novel treatments specifically for bipolar disorder. Deliberate (ie not by serendipity) treatments may come from one of two general mechanisms: ( 1) Understanding the mechanism of action of current medications and thereafter designing novel drugs that mimics these mechanism(s); ( 2) Basing medication development upon the hypothetical or proven underlying pathophysiology of bipolar disorder. In this review, we focus upon the first approach. Molecular and cellular targets of current mood stabilizers include lithium inhibitable enzymes where lithium competes for a magnesium binding site ( inositol monophosphatase, inositol polyphosphate 1-phosphatase, glycogen synthase kinase-3 (GSK-3), fructose 1,6-bisphosphatase, bisphosphate nucleotidase, phosphoglucomutase), valproate inhibitable enzymes ( succinate semialdehyde dehydrogenase, succinate semialdehyde reductase, histone deacetylase), targets of carbamazepine ( sodium channels, adenosine receptors, adenylate cyclase), and signaling pathways regulated by multiple drugs of different classes (phosphoinositol/protein kinase C, cyclic AMP, arachidonic acid, neurotrophic pathways). While the task of developing novel medications for bipolar disorder is truly daunting, we are hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.
引用
收藏
页码:734 / 755
页数:22
相关论文
共 264 条
[1]   Possible role of 3′(2′)-phosphoadenosine-5′-phosphate phosphatase in the etiology and therapy of bipolar disorder [J].
Agam, G ;
Shaltiel, G .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (05) :723-727
[2]   The potential role of PKC β in diabetic retinopathy and macular edema [J].
Aiello, LP .
SURVEY OF OPHTHALMOLOGY, 2002, 47 :S263-S269
[3]   LONG-LASTING INCREASE IN PROTEIN-KINASE-C ACTIVITY IN THE HIPPOCAMPUS OF AMYGDALA-KINDLED RAT [J].
AKIYAMA, K ;
ONO, M ;
KOHIRA, I ;
DAIGEN, A ;
ISHIHARA, T ;
KURODA, S .
BRAIN RESEARCH, 1995, 679 (02) :212-220
[4]   REDUCED BRAIN INOSITOL IN LITHIUM-TREATED RATS [J].
ALLISON, JH ;
STEWART, MA .
NATURE-NEW BIOLOGY, 1971, 233 (43) :267-&
[5]   Regulation of tau phosphorylation and protection against β-amyloid-induced neurodegeneration by lithium.: Possible implications for Alzheimer's disease [J].
Alvarez, G ;
Muñoz-Montaño, JR ;
Satrústegui, J ;
Avila, J ;
Bogónez, E ;
Díaz-Nido, J .
BIPOLAR DISORDERS, 2002, 4 (03) :153-165
[6]   Comparison of fluorescence, 31P NMR, and 7Li NMR spectroscopic methods for investigating Li+/Mg2+ competition for biomolecules [J].
Amari, L ;
Layden, B ;
Rong, QF ;
Geraldes, CFGC ;
de Freitas, DM .
ANALYTICAL BIOCHEMISTRY, 1999, 272 (01) :1-7
[7]   Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024 [J].
Ambrósio, AF ;
Soares-da-Silva, P ;
Carvalho, CM ;
Carvalho, AP .
NEUROCHEMICAL RESEARCH, 2002, 27 (1-2) :121-130
[8]  
Anderson R, 2001, J MOL NEUROSCI, V16, P279
[9]   Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression [J].
Angelucci, F ;
Aloe, L ;
Jiménez-Vasquez, P ;
Mathé, AA .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2003, 6 (03) :225-231
[10]  
ANLEZARK GM, 1976, BRIT J PHARMACOL, V56, pP383